New recommendations for radiation therapy in HPV-associated oropharyngeal cancer

Study title: Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline

Publication: Practical Radiation Oncology

Dana-Farber Cancer Institute author: Danielle Margalit, MD, MPH

Summary: A multi-disciplinary task force convened by the American Society for Radiation Oncology has issued new guidelines for radiation therapy for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). The expert task force recommends optimal dosing regimens for radiation therapy when used alone or after surgery, incorporating the latest data on minimizing doses to areas that may affect patient quality of life such as swallowing. Concurrent cisplatin chemotherapy is recommended for more advanced tumors or multiple lymph nodes.

For patients ineligible for cisplatin, a shared decision-making approach is emphasized and concurrent cetuximab, carboplatin/5-fluorouracil, or taxane-based systemic therapy are conditionally recommended. Recommendations are also given for post-treatment assessment of response to therapy.

The guideline additionally includes recommendations for postoperative settings.

Significance: New recommendations on the optimal use of radiation therapy for HPV-associated OPSCC are based on evidence from multiple clinical trials and aim to maintain good outcomes and reduce acute and late effects.

Funding: American Society for Radiation Oncology

Source:
Journal reference:

Margalit, D. N., et al. (2024) Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology. doi.org/10.1016/j.prro.2024.05.007.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Blocking nidogen-2 enhances chemotherapy efficacy in pancreatic cancer